Pierre Fabre acquisition
This article was originally published in The Rose Sheet
Executive Summary
French Pharmaceutical company forms Pierre Fabre Dermo Cosmetique USA subsidiary to acquire Genesis Pharmaceutical and C&M Pharmacal, marketers of Glytone and Wellskin skin care lines through dermatologists, firm announces Oct. 2. Acquisition is first step in Pierre Fabre's dermo cosmetic strategy in the U.S., company adds. Pierre Fabre will supplement Genesis' products with its own beginning with U.S. launch of Eau Thermale Avene, the company's main dermo cosmetic brand. New subsidiary will be headed by President Olivier Fontaine. Genesis President and CEO Leonard Mazur will retain his current position...
You may also be interested in...
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.